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ABSTRACT 
Transcriptional profiling was performed on 452 pancreatic tissues, with a focus on 
peritumoral samples. Pancreatic ductal adenocarcinomas (PDAC) and cystic tumours were 
most different in these non-tumorous, adjacent tissues, whereas the actual tumours exhibited 
more similar patterns. The environment of cystic tumours was transcriptionally nearly 
identical to normal tissue. In contrast, the tissue surrounding PDAC behaved a lot like the 
tumour, indicating some kind of field defect, and showed far less molecular resemblance to 
both chronic pancreatitis and healthy tissue. This suggests that the pathogenic difference 
between cystic and ductal tumours may also be influenced by their different cellular 
environment rather than variation between the tumours themselves. Little correlation 
between DNA methylation and transcript levels makes it unlikely that the field defect in PDAC 
peritumoral tissues is solely controlled by such epigenetic regulation. Functionally, a 
strikingly large number of autophagy genes was uniquely changed in both PDAC and its 
peritumoral tissue. A transcription signature of 15 autophagy genes permits a survival 
prognosis with high accuracy, highlighting the important role of autophagy in tumour biology. 
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INTRODUCTION 
Pancreatic cancer is one of the most aggressive tumours at all. Despite an incidence 
that represents only 3% of all cancer cases recorded in industrialised countries, it is the 
fourth most common cause of tumour-related deaths in the Western world (Ferlay et al., 
2015; Siegel et al., 2016). Among the different forms of pancreatic cancers, pancreatic ductal 
adenocarcinoma (PDAC) is accounting for more than 90% of all cases and has the worst 
prognosis; the other types are less lethal. Most PDAC patients die within a year of diagnosis; 
the overall five-year survival rate is about 5%. PDAC patients often and rapidly develop 
resistance to chemotherapy; the reasons for this are still largely unclear (Neoptolemos et al., 
2012; Werner et al., 2013; Habermehl et al., 2013). There is currently no efficient treatment 
available except surgery, which can only be applied to 10 to 20% of cases, however 
(Gurusami et al., 2014). For an improvement of the clinical situation, prognostic markers are 
required that allow predicting clinical progression more accurately (Costello et al., 2012). 
With the objective of understanding the molecular basis of pancreatic tumours, several 
studies of the RNA expression variation in pancreatic cancer have been performed (e.g., 
http://www.pancreasexpression.org/cgi-bin/pancexp/DataSets.pl). Substantial variations have 
been recorded between different studies, documenting technical variance as well as tumour 
heterogeneity (for meta-analyses see: Brandt et al., 2004; Bhasin et al., 2015). Also, several 
of these studies dealt with relatively few RNA samples and material from one hospital source 
only. In addition, only relatively few data sets are available on pancreatic tumour types other 
than PDAC. The same is true for non-tumorous pancreatic tissues and especially so for 
peritumoral samples from cancer patients. An accurate molecular differentiation of these 
tissue entities and a detailed understanding of their relation to the actual tumours are 
missing. 
In order to provide a more reliable source of information at several molecular levels 
on a large set of tumour and control samples – in particular including tissue samples that 
were close to tumour but not part of it – we performed extensive analyses on originally more 
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than 1000 pancreatic tissue samples collected by surgery at three major European pancreas 
clinics. At the DNA level, results on the mutational status of the KRAS and CDKN2A genes 
and their prognostic significance have been reported (Rachakonda et al., 2013). Also, the 
effect of several common polymorphisms on pancreatic cancer susceptibility and their 
possible impact on patient survival was published (Rizatto et al., 2011). Furthermore, 
suitability of microRNA variations and DNA methylation for diagnosis has been studied 
(Bauer et al., 2012; Keller et al., 2014, Moskalev et al., 2015) and was followed up by 
detailed investigations of their functional contributions to the disease (e.g., Botla et al., 2016).  
Here, we report about an analysis of transcriptional variations at the mRNA level 
performed on the basis of this large dataset. We identified significant variations between the 
various tumour forms, but also detected unexpected similarities between the mRNA 
expression patterns. Particularly striking was a substantial degree of similarity in 
transcriptional regulation between PDAC and the surrounding peritumoral cellular 
environment, indicating some kind of field defect. Interestingly, the transcriptional variation 
did not much coincide with changes in the DNA-methylation levels, which have been 
implicated in field defects (e.g., Wolff et al., 2010). Comparing cystic tumours and PDAC, 
most transcriptional differences took actually place in this peritumoral environment, while the 
transcriptional patterns in the tumour tissues were rather similar, suggesting a possible 
involvement of the wider cellular environment of a tumour in its pathology. Looking at the 
data from a functional angle, we inferred relevant pathways and possible functional 
consequences. Our findings highlighted the importance of autophagy-related transcript 
expression in the peritumoral environment of pancreatic tumours and the potential role of 
autophagy genes for prognosis and as legitimate targets for therapeutic intervention 
schemes.  
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RESULTS 
Comparison of transcriptional variations in different tissue types 
The study was performed on pancreatic tissue samples collected at three clinics in 
Heidelberg (Germany), Liverpool (UK) and Verona (Italy) by resection from cancer patients 
or donors, who had pancreatic tissue removed for reasons other than cancer. Sample 
analysis was performed in one central laboratory, following the same protocols throughout. 
From each sample, three tissue slices were evaluated by pathologists prior to further 
analysis, estimating the percentages of normal, tumour and stromal cells as well as the 
degree of inflammatory infiltration. In total, 452 RNA preparations met our quality standards 
and were included in the transcriptional profiling analysis. We studied a variety of tissue 
types. In particular, we looked at samples of non-tumorous tissue that had been located next 
to the actual tumour. These peritumoral tissues had been in a distance of up to 10 mm from 
the tumour and did not exhibit any tumour cell content in the histochemical analyses. They 
consisted of normal parenchyma and stroma and are referred to as “macro-environment” 
below. The 452 high-quality samples represented 195 cases of PDAC, 30 cases of PDAC 
macro-environment (N.PDAC), 24 cystic tumours (TC), 22 macro-environmental tissues from 
next to cystic tumours (N.TC), 59 samples of chronic pancreatitis (CP), 15 tissues from the 
macro-environment of CP (N.CP), and 41 healthy pancreatic tissues from non-cancer 
patients (N). Other neoplasms, for which RNA was isolated but ignored in the analysis 
reported below, were 18 endocrine tumours, 2 macro-environmental samples of endocrine 
tumours, 31 other pancreatic tumours as well as 15 related macro-environment tissues. 
Information about clinical patient parameters is given in Tab. 1.  
Many genes exhibited changes at the transcript level in the various tissue types 
compared to samples from healthy donors (Fig. 1) (see also Tab. EV1). Also, a large number 
of changes were found that were common between different tissues (Fig. 2). It is noteworthy 
that this means a variation in the same direction (up or down, respectively) as compared to 
the normal tissue and not an increase in one and a decrease in the other tissue. As a matter 
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of fact, an analysis revealed that all genes, which showed a significant variation in two 
tissues, were similarly regulated either up or down in both when comparing N.PDAC, PDAC 
and cystic tumours (Fig. 2E). This complete lack of inverse regulation suggests that 
functionally similar cellular effects are triggered by these common transcriptional changes. 
Particularly interesting results were obtained from the macro-environments of PDAC 
and cystic tumours, which histologically showed a similar cell composition. Compared to the 
transcript profiles obtained from normal tissue, a large number of genes were found 
differentially transcribed in the PDAC macro-environment, indicating that the phenotypically 
non-tumorous appearance does not represent the actual molecular status (Fig. 2A). In 
addition, there was a substantial overlap of 2,641 genes with the results obtained from 
PDAC, of which 1,997 were also changed in CP. At a transcriptional level, the PDAC macro-
environment and tissue of patients with CP were similarly different to normal tissue. 
However, PDAC macro-environment exhibited significantly more molecular resemblance with 
tumour tissue than with CP. For cystic tumours, there was a rather different picture. The 
overlap with the transcriptional pattern of CP was identical in number to the overlap of PDAC 
and CP (Fig. 2B). However, in contrast to the PDAC result, the macro-environment of cystic 
tumours behaved very similar to normal pancreatic tissue with only 343 differentially 
transcribed genes as opposed to 2909 genes in the PDAC macro-environment. In a 
comparison of the macro-environments of PDAC and cystic tumours (Fig. 2C), only 45 
differentially expressed transcripts were found to be specific for the macro-environment of 
cystic tumours.  
 
Variations that are specific to PDAC and its macro-environment 
Since PDAC represents the vast majority of clinical pancreatic cancer cases and has 
the worst prognosis, we focussed our analysis on this tumour type. More than half of the 
5,196 genes that exhibited significant variations in PDAC compared to healthy tissue were 
also differentially expressed in PDAC macro-environment or CP tissues (Fig. 2A). The 1,997 
regulated genes shared between the three tissue types mostly represent changes that are 
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associated with inflammation. The most overrepresented canonical pathways defined by 
these genes are relevant for immunological and inflammatory response (Fig. EV1). Next to 
the shared transcript variations, there were (marker) genes that exhibited expression 
changes that were unique to each tissue type. The six most significant biological functions 
associated with the 2,373 unique PDAC expression markers are: cellular growth and 
proliferation; cellular movement; cell death and survival; cancer; cell cycle; as well as 
organismal injury and abnormalities (Fig. 3). There were no over-represented functions that 
are associated with inflammation. In contrast to this, the 127 and 162 markers that were 
unique to the PDAC macro-environment or CP, respectively, are genes over-representing 
functions associated with both inflammation and cancer. 
Of particular interest are the 644 regulated transcripts shared between PDAC and its 
macro-environment, but not regulated in CP (Fig. 2A; Tab. EV2). The fact that the non-
tumorous macro-environment tissue exhibited a large number of variations, which are 
common with PDAC only, suggests the possibility of a cancer field defect at the transcript 
level. A cancer field defect is defined as a biological cancerisation process in which tissue in 
relatively large areas beyond the actual tumour is exhibiting epigenetic changes similar to the 
ones of the actual tumour (Shen et al., 2005; Yan et al., 2006; Wolff et al., 2010; Botla et al., 
2012). Methylation changes are expected to result in variations at the transcript level, too. To 
reveal the degree by which promoter methylation may be responsible for the observed 
variations at the RNA level, we analysed the genomic DNA of 24 randomly selected samples, 
12 each from healthy donors and PDAC patients, from which we had also obtained mRNA 
profiles. In the set of 644 transcripts shared by PDAC and its macro-environment, 154 genes 
exhibited an inverse correlation of promoter methylation and mRNA expression: 115 hyper-
methylated promoters could be linked to down-regulation of the mRNA level, 39 hypo-
methylated promoters coincided with transcripts that were present in higher abundance. 
However, for the majority of genes, 490, there was no such correlation of promoter DNA 
methylation and gene expression. For 76 genes, there was even a concurrent increase or 
decrease, respectively, of both methylation and mRNA level.  
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Pathways and gene networks affected in the macro-environment of PDAC 
Transcripts showing significant expression differences in the macro-environment of 
PDAC as compared to healthy control samples were submitted to a functional bioinformatics 
examination using Ingenuity pathways analysis. In this analysis, one particular network of 
genes was identified. It consists of 73 directly linked genes (Fig. EV2; Tab. EV3). Many 
genes show a gradual change of expression from healthy via CP to PDAC macro-
environment and finally PDAC. Two typical examples are the chemokine receptor CXCR4 
(chemokine (C-X-C motif) receptor 4) and NUPR1 (nuclear protein transcriptional regulator 
1). CXCR4 is a prognostic marker in various types of cancer (Furusato et al., 2010) and a 
biomarker of migrating pancreatic cancer-initiating cells in mice (Wang et al., 2013). It was 
up-regulated compared to normal tissue by a factor of 3.51 in CP, 4.38 in the macro-
environment and 6.68 in PDAC.	  NUPR1 interacts with numerous partners to regulate cell 
cycle, apoptosis, autophagy, chromatin accessibility, and transcription (Cano et al., 2011) 
and reduced expression promotes pancreatic cancer development (Hamidi et al., 2012). It 
was down-regulated by -1.80 (CP), -2.10 (macro-environment) and -2.41 (PDAC). Numerous 
genes within the network are essential in Pancreatic Adenocarcinoma Signalling, as well as 
the Integrin-Linked Kinase (ILK) and mTOR Signalling pathways. ILK is known to transmit 
mechanical stimuli to the mammalian target of the mTOR Signalling pathway (Dwayne et al., 
2002). mTOR is an evolutionarily conserved serine/threonine protein kinase that integrates 
both intracellular and extracellular signals and serves as a central regulator of cell 
metabolism, growth, proliferation, survival, and autophagy (Neufeld, 2009). The Akt/mTOR 
pathway mediates oncogenesis and controls tumour cell growth (Shaw and Cantley, 2006). 
Based on these findings, we took a closer look at these pathways (Fig. EV3). 
Interestingly, in the Pancreatic Adenocarcinoma Signalling pathway, 35 of the 106 genes 
(33%) are annotated as relevant to autophagy. For ILK/mTOR Signalling, the absolute 
number of autophagy-related genes was even higher with 54 molecules out of 186, although 
the percentage was slightly lower with 29%. The observed considerable overrepresentation 
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of autophagy-associated genes within the pathways suggested a strong link between 
autophagy and pancreatic cancer. This was corroborated by the overall number of autophagy 
genes found to be regulated in PDAC. Of the genes that were assayed in the transcriptional 
profiling experiments, 512 are annotated to be associated with autophagy processes 
according to public autophagy databases (Homma et al., 2010; Moussay et al., 2011). Of 
these, 88 genes were regulated in CP compared to normal tissue. In the macro-environment, 
this number increased to 108 genes, while a total of 208 genes were regulated significantly in 
PDAC (Tab. EV4). Given the obvious importance of autophagy for pancreatic cancer and the 
fact that about 40% of all autophagy genes were significantly regulated in PDAC or in the 
PDAC macro-environment, we focussed further analyses on those genes. 
 
Autophagy genes in PDAC, cystic tumours and macro-environment  
In our data set, there were several autophagy genes that are known markers for 
pancreatic cancer. Examples are ATG3, ATG4A, ATG4B, ATG4C and ATG5 (Devenish et 
al., 2012); they showed down-regulation in PDAC and its macro-environment. Also the ductal 
transcription factor HNF6 (ONECUT1) was found to be less expressed. Such a reduction in 
HNF6 expression correlates with human pancreatic cancer progression (Pekala et al., 2014). 
HNF6 has also been described as biomarker for acinar-to-ductal metaplasia (Prevot et al., 
2012) suggesting that a phenotypic switch converting pancreatic acinar cells to duct-like cells 
could lead to pancreatic intraepithelial neoplasia and eventually to invasive PDAC. 
Furthermore, HNF6 is a transcription regulator of the UDP glucuronosyltransferase (UGT) 
family members UGT2B11 and UGT2B15, which were also less expressed in PDAC and its 
macro-environment. Interestingly, variations in the UGT genotype are associated with an 
altered risk to pancreatic cancer (Ockenga et al., 2003). None of the above genes was 
regulated in the macro-environment of cystic tumours. As mentioned before, this is actually 
true for the majority of regulated mRNAs. Many were significantly differentially transcribed in 
CP, PDAC macro-environment, PDAC and cystic tumours but not in the macro-environment 
of cystic tumours (Fig. 2C). As cystic tumours are known to have a much better prognosis in 
10	  
comparison to PDAC (Basturk et al., 2009), factors that are regulated in the macro-
environment of PDAC but not in the macro-environment of cystic tumours might be relevant 
for the much more aggressive nature of PDAC.  
 
Autophagy-related prognostic markers 
Given the apparent importance of autophagy genes as specific markers of the tumour 
and the macro-environment of PDAC, we wondered whether they may act as a clinically 
relevant surrogate for disease and might have prognostic significance. In order to investigate 
this, the relationship was explored between patient survival and several explanatory 
variables. First, we performed a multivariable analysis to learn about the influence of the 
factors age, gender, tumour grading, treatment, smoking, and alcohol consumption. Their 
risk coefficients were insignificant, except for tumour-stage with a p-value of 0.0018. Then, 
the effect of gene expression was investigated for each gene individually. In total, 35 
autophagy-related transcripts were differentially transcribed in PDAC and statistically linked 
to survival time (Tab. EV5). Eighteen genes were regulated in both PDAC and its macro-
environment (Tab. 2). The top-candidates were PRAF2, PLK4, ACTB and PKM2. The 
transcript levels were confirmed by qRT-PCR, fitting to the microarray data in all cases (Fig. 
EV4). Interestingly, neither PRAF2 nor PLK4 had been connected to PDAC so far. With 
respect to prognosis, the expression of the two genes corresponded well with survival time 
and matched the performance of hypoxia-inducible factor 1 alpha (HIF1A) (Fig. 4), whose 
change in expression has been shown to have a strong impact on the prognosis of patients 
with PDAC (Sun et al., 2007; Hoffmann et al., 2008).  
Based on the analysis of the prognostic value of the expression of individual genes 
and by cross-referencing this with the list of autophagy-related genes that are differentially 
expressed in PDAC and its macro-environment, we identified the most-informative signature, 
which consists of 15 genes: ACTB, ANTXR1, CAMK1G, DLG4, DNAJB9, EIF2AK3, ITPR1, 
MPDZ, MYO5C, NLE1, P4HB, PKM2, PLK4, PRAF2 and WDFY2 (Fig. EV5). In combination, 
the selected genes showed a strong statistical linkage to survival in a Cox regression model 
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(p-value = 8x10-15). Next, we classified patients by a support vector machine as described in 
the Methods section: our classifier discriminated “good” and “poor” prognosis patients. As a 
basis, they were divided into two groups based on their survival in relation to the median 
survival time. The classification was performed 1000 times yielding an average accuracy of 
82.6±0.1%. The discriminating power of the signature is shown in a Kaplan-Meier plot (Fig. 
5), indicating the substantial difference in survival between the patients with a good 
prognosis and the group with bad prognosis.  
 
 
DISCUSSION  
We performed transcriptional profiling on various types of pancreatic tissue samples, 
focussing particularly on changes in tissues that were located next to actual tumours. 
Comparison of the expression data documented that PDAC and cystic tumours are not that 
different at the transcriptional level, even though 892 and 516 genes, respectively, had 
expression patterns that were unique to either tumour type. However, variation in 4179 
genes was in common. In addition, both tumour types shared a rather similar set of 
transcriptional variations with CP tissues, indicating the substantial contribution of 
inflammatory aspects that are relevant for tumour pathology. The most significant difference 
between PDAC and cystic tumours was actually found in their surrounding, non-tumorous 
tissues. Histologically, they exhibited a similar cell composition. However, while the PDAC 
macro-environment behaved in part like the actual tumour, the macro-environment of cystic 
tumours was transcriptionally nearly identical to normal pancreas tissue. This suggests that 
major differences between cystic tumours and PDAC may not be solely intrinsic to the actual 
tumours, but be triggered indirectly by the way tumours influence or are influenced by their 
wider cellular environment.  
Assuming that a field defect could be responsible for the large number of genes, 
which were identically regulated in PDAC and its macro-environment, and that it may be 
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resulting from DNA methylation processes, which have been implicated in field defects (Shen 
et al., 2005; Yan et al., 2006; Wolff et al., 2010; Botla et al., 2012), we studied how the 
degree of promoter methylation correlated with the transcriptional variations. Surprisingly, the 
degree of inverse correlation – hyper-methylation and low expression, hypo-methylation and 
high expression – was rather low overall. One possible explanation for this observation could 
be the presence of processes other than DNA methylation, which regulate transcription. Any 
such mechanism must be rather efficient in transporting the information, since the effect 
could be detected over distances of several millimetres. MicroRNA transport in cellular 
vesicles, such as exosomes, and absorption by recipient cells has been shown to have such 
effects (e.g., Costa-Silva et al., 2015). In the intracellular space, one would expect a gradient 
in the concentration of exosomes radiated by tumours and a related gradient in the degree of 
cellular transcriptional variations. The actual distance of the macro-environmental samples 
analysed in this study was inadequately annotated so as to identify such an effect.  
Alternatively, it could be that only very few genes and their methylation may be 
initiating the field defect. Gene NR5A2 (encoding the nuclear receptor subfamily 5, group A, 
member 2) was found to be one of the genes, which was both hyper-methylated and down-
regulated in PDAC and PDAC macro-environment. NR5A2 had not been described as a 
methylation marker of PDAC before. However, single nucleotide polymorphisms in the 
vicinity of NR5A2 have been linked through genome-wide association studies to the risk of 
developing PDAC, suggesting a broader role of this gene in pancreatic homeostasis and 
disease (Petersen et al., 2010). It was shown that NR5A2 heterozygosity correlates with 
pancreatic damage in the progression of mutant KRAS-driven preneoplastic lesions, 
suggesting that NR5A2 could contribute to PDAC through its role in the recovery from 
pancreatitis-induced damage (Flandez et al., 2015). The gene might be an interesting 
candidate for exploring a potential cancer field defect in pancreatic cancer. With respect to 
clinical utility, a field defect in the non-tumorous tissue and the identification and validation of 
relevant molecular variations at the RNA level or the degree of DNA methylation could allow 
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the establishment of effective disease biopsy markers, since they would also be present in a 
wider distance to the actual tumour and therefore be easier to collect. 
One cannot rule out that other mechanisms than the ones above might be 
responsible for the field defect. For example, surgeons and pathologists observe that 
peritumoral tissues in patients with PDAC are apparently altered phenotypically, while tissues 
adjacent to cystic or neuroendocrine tumours often look quite normal. The mere degree of 
expansion of PDAC and the resulting obstruction of the macro-environment could be 
triggering transcriptional variations that also occur in PDAC tissue itself but not in or around 
the slowly growing cystic tumours thus providing a simple mechanical explanation for the 
differences. Further studies are required to define the relevant molecular processes in more 
detail. 
Our findings particularly indicate the importance of autophagy transcripts in the 
macro-environment of pancreatic tumours and their potential role as prognostic markers. 
Autophagy is an evolutionarily conserved catabolic process, by which a cell digests its own 
cytoplasmic content. Autophagy is activated in reaction to multiple stress factors during 
cancer progression, such as hypoxia and poor nutrient supply (Fortunato et al., 2009) and 
has an important role in tumour development (Kondo et al., 2005; Newman et al., 2007). 
Overall, the dynamic role of autophagy in cancer appears to be complex and context-
dependent. On the one hand, it could function as a tumour suppressor, whose inactivation 
promotes tumorigenesis (Liang et al., 1999; Mathew et al., 2009), on the other hand, it may 
act as a pro-survival pathway that helps tumour cells to handle metabolic stress and to resist 
chemotherapeutic agents (Kimmelman, 2011). In pancreatic cancer, autophagy is required 
for tumour growth (Yang et al., 2011; 2014) and mediates survival of pancreatic-tumour-
initiating cells in a hypoxic microenvironment (Rausch et al., 2012). Inhibition of autophagy 
reduced pancreatic cancer growth independent of the p53 status (Yang at al., 2014). 
Furthermore, autophagy was shown to be essential for oncogenic KRAS-induced malignant 
cell transformation (Kim et al., 2011). There are several early-phase clinical trials in progress 
targeting the autophagic machinery, among them a study of MEK1/2 and AKT inhibitors in 
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patients with KRAS-driven pancreatic tumours (Tolcher et al., 2015). Other studies have 
suggested that autophagy is involved in a broad crosstalk to multiple pathways that 
determine cell fate, including apoptosis (Marino et al., 2014).  
The increased recognition of the active role of autophagy in tumorigenesis has led to 
the identification of novel autophagy markers for prognosis prediction (Lazofa et al., 2012). 
Prognostic significance of autophagy-related protein expression in resected pancreatic ductal 
adenocarcinoma has been described (Ko et al., 2013). In our study, the regulation of several 
autophagy-associated genes correlated with survival-time. Of special interest are the 
prognostic factors that were particularly regulated in pancreatic cancer and its macro-
environment, such as PRAF2 and PLK4, as these transcripts might be useful in 
distinguishing inflamed versus oncogenically transformed regions of the pancreas. PRAF2 
(Prenylated Rab acceptor 1 domain family, member 2) is a small transmembrane protein with 
a putative role in transport from the endoplasmic reticulum to the Golgi apparatus (Ruggiero 
et al., 2008). It induces apoptotic cell death upon expression and is counteracted by Bcl-xL 
(Vento et al., 2010). It stimulates cell proliferation and migration and predicts poor prognosis 
in neuroblastoma and glioma (Borsics et al., 2010; Yco et al., 2013). PLK4 (Polo-like kinase 
4) is a conserved upstream regulator of centriole duplication (Habedanck et al., 2005). It is 
aberrantly expressed in different tumour types (Chng et al., 2008; Salvatore et al., 2007), 
causing a loss of centrosome numeral integrity, thereby promoting genomic instability 
(Holland et al., 2010). Recently, a drug discovery programme identified a potent and 
selective small molecule inhibitor of PLK4 (Sampson et al., 2015), which may have 
therapeutic implications for PDAC as well.  
Already some individual differentially expressed autophagy transcripts allowed a 
disease prognosis that is equivalent to markers reported before. By combining 15 autophagy 
genes, we obtained a signature, which allowed an even better classification of patients into 
groups with good or bad prognosis. Even though some of these transcripts exhibited an only 
modestly differential expression in PDAC, they documented a significant prognostic power. 
An analysis of these transcripts may offer a means for a better prognosis after tumour 
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resection, although limitations apply for utilising actuarial probabilities for a prediction of the 
actual survival of an individual patient (Grunkemeier et al., 2007). However, the analysis 
highlights the importance of autophagy for tumour pathology and indicates that this process 
is likely be highly relevant for future treatment strategies and monitoring of its success.  
 
 
MATERIALS AND METHODS 
Tissue samples and histopathology 
Human pancreatic tissue samples were collected during surgery. In all cases, written 
informed consent was obtained from the patients. The study was approved by the local 
ethics committees at the universities of Heidelberg, Verona and Liverpool. The samples were 
snap-frozen in liquid nitrogen directly after resection and subsequently stored at -80°C until 
being used in the analysis. All samples were analysed at DKFZ following identical 
procedures. The frozen tissue was cut into slices of 15 µm thicknesses with a Leica CM 1850 
UV cryotome at -34°C; three slices were picked from the top, middle and bottom third of a 
tumour and immediately used for histopathology. All remaining slices were mixed to assure 
equal representation of the entire tissue sample and split into three aliquots, which were 
used for separate preparations of DNA, RNA and protein. 
For a histopathological assessment of each sample’s cellular composition, the three 
tissue sections were stained with hematoxylin and eosin (H&E staining). They were scanned 
with a ScanScope GL system (Aperio Technologies, Vista, USA) and visualised using the 
accompanying ImageScope software. For each tissue sample, pathologists evaluated 
independently the histology and estimated the percentages of normal, tumour and stroma 
cells.  
 
16	  
DNA methylation profiling 
DNA was isolated with the AllPrep Isolation kit (Qiagen, Hilden, Germany), following 
the manufacturer’s protocol. For DNA methylation analysis, we performed on 12 normal and 
12 PDAC samples the Infinium Human Methylation 450 BeadChip assay of Illumina (San 
Diego, USA), which interrogates 485,000 methylation sites across the human genome, using 
1 µg of DNA per sample. The procedure followed the manufacturer’s standard workflow, 
starting with the bisulfite conversion of the DNA samples using the EpiTect Bisulfite kit 
(Qiagen). Bisulfite-converted DNA acted as template for whole-genome amplification, 
enzymatic digestion, followed by a DNA clean-up process and hybridisation to the BeadChip. 
The samples were washed and scanned with the BeadArray Reader (Illumina). From the 
signal intensities, the DNA methylation was analysed using the Illumina Bead studio 
software.  
 
Transcriptional profiling 
For RNA isolation, the aliquot of frozen tissue slices allocated for RNA preparation 
was submerged in liquid nitrogen and gently ground by three turns with a polypropylene 
micropestle (Eppendorf, Hamburg, Germany) in a 2 ml Eppendorf tube. Total RNA was 
isolated with the AllPrep Isolation kit (Qiagen), following the manufacturer’s protocol. RNA 
integrity was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, 
USA). Only samples with an RNA integrity number of at least seven were used for further 
analyses. 
The total RNA prepared from individual samples was analysed on Sentrix Human-6v3 
Whole Genome Expression BeadChips (Sentrix Human WG-6; Illumina). To synthesize first 
and second strand cDNA and for amplifying biotinylated cRNA, the Illumina Totalprep RNA 
Amplification kit was used. Hybridisation to the BeadChip was performed according to the 
manufacturer's instructions. In short, a maximum of 10 µl cRNA was mixed with 20 µl GEX-
HYB hybridisation solution. The 30 µl sample was preheated, dispensed into the large 
sample-port of each array and incubated on the array at 58°C for 18 h. Subsequently, the 
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arrays were washed and scanned with a BeadArray Reader (Illumina). An application of low 
quality samples yielded higher background combined with weaker signal intensities. Such 
results were significantly less accurate and reproducible and therefore ignored in the 
discovery phase. 
 
Data analysis 
Preprocessing and quality control. Raw data were exported from the Illumina 
Beadstudio software and processed by R/Bioconductor scripts (Ritchie et al., 2011). The 
data was quantile normalised and log2 transformed. Distribution and quality of the expression 
data was performed using principle component analysis (PCA) and hierarchical clustering. 
The raw and normalised data are accessible at the public database ArrayExpress (DNA 
methylation profiling ID: Reviewer E-MTAB-3855; password “pyzqdbii“; transcriptional 
profiling ID: Reviewer_E-MTAB-1791; password: “rpqqrysi”). 
Differential expression analysis. Significant differentially expressed transcript features 
were detected using the LIMMA package of R/Bioconductor (Smyth et al., 2004) by pairwise 
comparisons of the groups (e.g., PDAC vs. normal, chronic pancreatitis vs. normal, etc.). The 
resulting p-values were adjusted for multiple testing using Benjamini-Hochberg’s false 
discovery rate (FDR) method (Benjamini and Hochberg, 1995); features with a FDR<0.01 
and an absolute log2-fold change |log2FC|>0.5 were considered significant. Transcript 
features were annotated by gene symbols; we only report results for distinctly annotated 
genes, in order to avoid bias caused by genes, which are represented on the array with 
multiple probes. For a functional enrichment analysis, the Ingenuity PA software tool 
(Ingenuity Systems, http://www.ingenuity.com) was applied. 
Survival analysis. Cox’s proportional hazards models were used for exploring the 
relationship between the survival of a patient and several explanatory variables, including 
phenotypic parameters and gene expression. Analysis was performed on PDAC patients 
utilising the survival package of R/Bioconductor (Terry et al., 2000). This analysis returns 
statistical significance of prognostic variables included into the model and allowed us to 
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estimate the risk of death for individuals. A positive regression coefficient for an explanatory 
variable at high significance level means that the hazard is higher, and thus the prognosis is 
worse. Conversely, a negative regression coefficient implies a better prognosis for patients. 
We started with checking the effect of phenotypical parameters: age, gender, cancer stage, 
smoking and alcohol intake. Then the effect of gene expression was investigated for each 
gene independently and FDR-adjusted p-values of a Wald test were assigned to them. 
Signature selection amongst autophagy genes. We used the intersection among 
significant genes in order to identify autophagy genes, which can be used as prognostic 
signature for PDAC. Before analysis, we summarized microarray features to the gene level in 
order to merge data from features targeting the same gene. Genes were selected that were 
differentially expressed, linked to survival by Cox regression (FDR<0.01) and annotated as 
autophagy-related genes in relevant literature and databases (Homma et al., 2010; Moussay 
et al., 2011). In order to transform expression intensity values of genes to a single value, we 
used an approach presented before (Collura et al., 2013). Gene expression values were 
median-centred, and expression values of genes with a negative Cox’s coefficient were 
inverted by multiplication by minus one in order to account for a survival effect. Then, gene 
expression of each patient was summed up forming a single score. Predictive power of the 
signature was characterised using support vector machine (SVM) as a classifier. Similar to 
Lu and colleagues (Lu et al., 2006), cancer patients were divided into two groups with “good” 
and “poor” prognosis based on their survival in relation to median survival time of the 
patients. Gene expression was used as input to a support vector machine classification; 
output was considered as a binary signal for “good” or “poor” survival. During performance 
testing, 80% of the patients were randomly selected and divided into two groups, keeping a 
correct proportion of good/poor prognosis patients. This operation was repeated 1000 times 
in order to characterise confidence intervals for accuracy (ratio between numbers of correctly 
classified patients to total number).  
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Pathway analysis of differentially expressed genes 
Differentially expressed transcripts were mapped onto a molecular network developed 
from information contained in the Ingenuity knowledge base (Ingenuity Systems, 
http://www.ingenuity.com). Networks of these genes were generated based on their 
interconnectivity. Ingenuity Pathway Analysis ranks the resulting networks by calculating a 
significance score corresponding to the negative log of p-value. Furthermore, pathway core 
analysis identified the pre-specified canonical pathways that were most over-represented in 
the data set. Fisher's exact test was used to calculate a p-value for the association between 
the genes in the data set and the canonical pathway or network.  
 
RT-PCR confirmation 
For RT-PCR, 1 µg total RNA of 20 samples per group (normal pancreas, PDAC and 
its macro-environment) was reverse-transcribed using the ProtoScript M-MuLV First Strand 
cDNA Kit (New England Biolabs, Frankfurt, Germany). Quantitative RT-PCR was performed 
in triplicate on a LightCycler 480 (Roche Diagnostics, Mannheim, Germany) with a pre-
amplification incubation of 95°C for 10 min, followed by 45 cycles of 95°C for 10 sec and 
55°C for 30 sec. The following molecules of the QuantiTect Primer Assays (Qiagen) were 
used as primers: Hs_ACTB_1_SG, Hs_PKM_1_SG, Hs_PLK4_1_SG, Hs_PRAF2_1_SG 
and Hs_BUD13_1_SG. BUD13 was used as reference gene as it showed constant mRNA 
expression in all 452 analysed pancreatic tissue samples and an adequate expression level. 
Data were analyzed using the LightCycler software (Roche) and relative fold changes were 
calculated using the 2−ΔΔCt method (Bookout et al, 2006). 
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THE PAPER EXPLAINED 
Problem 
Pancreatic ductal adenocarcinomas (PDAC) and cystic tumours of the pancreas differ 
widely in their mortality. In most cases, the former kills patients within few months after 
diagnosis, while patients with the latter tumour have a much better prognosis. Also, non-
tumorous samples from areas adjacent to the tumour are considered to differ from the 
tumour as much as healthy tissues do, but for the personal genetic background. Looking at 
the transcriptional variations in both tumour types and by comparing the transcriptional 
signatures of peritumoral tissues, we aimed at identifying molecular differences and 
similarities between the different tissue types and thus studying the influence of the 
peritumoral tissue on tumour development and prognosis. 
Results 
The peritumoral environment of cystic tumours was transcriptionally nearly identical to 
normal tissue. In contrast, the tissue around PDAC behaved much like the tumour, indicating 
some kind of field defect. At the same time, it was as different to chronic pancreatitis as to 
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healthy tissue. Very little correlation between the degree of methylation of promoter regions 
and the regulation of the respective genes was observed, suggesting a mechanism for the 
field defect other than methylation. Functionally, a strikingly large number of autophagy 
genes was uniquely changed in both PDAC and its peritumoral tissue. The relevance of 
autophagy for tumour pathology was demonstrated by the ability to predict patient survival 
with good accuracy on the basis of the expression of 15 autophagy genes. 
Impact 
The results suggest that the pathogenic difference between cystic and ductal tumours 
could – at least in part – be due to their cellular environment rather than variation between 
the tumours. Also, the importance of autophagy for PDAC pathology was highlighted. 
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FIGURES LEGENDS 
 
 
 
Figure 1. Heatmap representing the relative signal intensities of the most differentially 
expressed genes in all analysed samples. The complete dataset is provided in Tab. EV1; 
here, the top 50 genes of each comparison are shown: PDAC/N; PDAC/N.PDAC; 
N.PDAC/N. Columns represent individual samples; the bar at the top indicates their clinical 
annotation. In the rows, the genes are shown. If a gene name is listed more than once, it was 
represented on the microarrays by different features. The median of all normalised signal 
intensities was determined and is represented by white cross-sections. The intensity of the 
red and blue colour at cross-sections indicates the degree by which gene expression in this 
sample was higher or lower (at a log2 scale), respectively, than the median value.	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Figure 2. Tissue specificity of mRNA level variations. For each tissue type, the number of 
mRNAs is shown that were significantly differentially expressed in comparison to normal 
pancreas tissue (N). The numbers in overlap regions stand for genes, regulated similarly in 
the relevant tissues. (A) Results are presented for PDAC, the related macro-environment 
(N.PDAC) and chronic pancreatitis (CP), marked in red, green and yellow, respectively. (B) 
The panel presents the same for cystic tumours (TC; brown), the related macro-environment 
(N.TC; blue) and again chronic pancreatitis (CP; yellow). (C) The macro-environment of 
cystic tumours (N.TC) exhibited relatively few variations at the mRNA level that were specific. 
(D) Presentation of the result of a comparison of all five data sets. (E) Correlation in the 
direction of variation observed for N.PDAC/N (top panel) or TC/N (bottom panel), 
respectively, in comparison to PDAC/N. Both axes represent the score shown above the 
panels, thus focussing on the most significant variations (shown in blue). Grey dots, mostly 
close to the centroid, represent insignificant changes. 
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Figure 3. Most overrepresented biological functions associated with the 2,373 unique 
marker genes of PDAC. The intensity of the purple colour of the squares is proportional to 
the number of genes that are associated with each function. The size of the squares reflects 
the associated negative log10 of the assigned p-value. Larger squares indicate a more 
significant overlap between the genes perturbed in the dataset and the respective function. 
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Figure 4. Linkage of gene expression levels in PDAC and patient survival time. Four 
typical Kaplan-Meyer curves with 95% confidence (dotted lines) are shown. An increase in 
expression of PRAF2 is linked to poor survival, whereas stronger PLK4 expression predicts 
better survival. In the third panel, the result is shown for the established prognostic marker 
HIF1A, which is linked to poor survival. The expression of ABL1 is not correlated to survival 
time at all and shown as a reference. The p-values shown are based on a Cox regression of 
continuous log2 gene expression. 
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Figure 5. Prognosis of patient survival. Kaplan-Meier curves were calculated based on an 
expression signature in PDAC of the 15 genes named in the figure (logRank p-value of Cox 
model = 8.44 x 10-15). In blue, the survival of the patients with good prognosis is shown; the 
red line represents the result of the patients with poor prognosis. The dotted lines correspond 
to 95% confidence intervals. 
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TABLES 
 
Table 1. Clinical characteristics of patient cohort. Details are listed of the clinical 
parameters of the patients from whom the 452 RNA-preparations were isolated and 
subsequently analysed. N = healthy tissue; CP = chronic pancreatitis; PDAC = pancreatic 
ductal adenocarcinoma; N.PDAC = macro-environment of PDAC; TC = cystic tumour; N.TC 
= macro-environment of cystic tumour; n/a = not applicable. 
 
  N CP PDAC N.PDAC TC N.TC Others 
No. of patients 41 58 195 30 24 22 82 
Gender 
(male / female) n/a 48 / 10 109 / 86 21 / 9 7 / 16 4 / 18 50 / 32 
Age at surgery, 
median (range) n/a 
47.1 
(13-73) 
63.4 
(40-85) 
60.8 
(34-84) 
62.0 
(23-75) 
57.1 
(38-75) 
55.7 
(13-86) 
Stage 
       
0 n/a n/a - - 1 - - 
IA n/a n/a - - 1 - 1 
IB n/a n/a 1 - 1 - 1 
IIA n/a n/a 21 5 - 3 5 
IIB n/a n/a 123 18 4 1 24 
III n/a n/a 7 - - - 2 
IV n/a n/a 17 2 2 - 4 
Median survival-
time in months, 
(range) 
n/a n/a 24.7 (1-159) 
19.7 
(1-65) 
14.7 
(3-36) 
22.2 
(4-53) 
18.22 
(1-54) 
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Table 2. Result of a Cox regression of 18 autophagy transcripts statistically linked to 
survival time. A positive coefficient indicates a worse prognosis, a negative coefficient a 
protective effect. In addition, the regulation in PDAC and PDAC macro-environment 
(N.PDAC) as compared to healthy tissue is shown. FRD: false discovery rate; log2FC: 
logarithm of fold change. 
 
Gene Cox Coeff. 
Cox 
FDR 
PDAC 
log2FC 
PDAC 
FDR 
N.PDAC 
log2FC 
N.PDAC 
FDR 
PKM2 0.617 0.0004 1.475 0.000 0.702 0.000 
ANTXR1 0.601 0.0088 1.373 0.000 0.843 0.000 
ACTB 1.087 0.0023 1.298 0.000 0.768 0.000 
CAMK1G -0.410 0.0008 1.140 0.000 1.015 0.001 
PLK4 -0.633 0.0034 0.991 0.000 0.529 0.000 
VIM 0.421 0.0166 0.846 0.000 0.865 0.000 
DLG4 0.570 0.0001 0.761 0.000 0.902 0.000 
ITPR1 -0.704 0.0017 0.741 0.000 0.816 0.000 
MPDZ -0.685 0.0038 0.613 0.000 0.729 0.000 
PRAF2 1.068 0.0000 0.588 0.000 0.595 0.000 
EIF2AK3 0.846 0.0014 -0.715 0.000 -0.501 0.001 
SH3GLB2 -0.550 0.0198 -0.726 0.000 -0.713 0.000 
NLE1 1.153 0.0050 -0.728 0.000 -0.532 0.000 
MYO5C -0.407 0.0036 -0.818 0.000 -0.780 0.001 
MAP2K7 0.697 0.0179 -0.901 0.000 -0.608 0.000 
P4HB 0.550 0.0057 -1.079 0.000 -0.592 0.003 
WDFY2 -0.822 0.0052 -1.192 0.000 -0.915 0.000 
DNAJB9 -0.598 0.0069 -1.300 0.000 -0.904 0.000 
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EXPANDED VIEW FIGURES 
	  
	  
	  
Figure EV1. List of the most overrepresented canonical pathways shared between 
PDAC, chronic pancreatitis and PDAC macro-environment. The bar chart displays for 
each canonical pathway the percentage of genes in the pathway that were found overlapping 
with the dataset of 1,997 regulated genes shared between PDAC, PDAC macro-environment 
and chronic pancreatitis. The numerical value to the right of each bar represents the total 
number of genes in the canonical pathway. The Benjamini-Hochberg method was used to 
adjust the right-tailed Fisher's Exact t-test p-value, displayed as negative log10 value by the 
orange squares. 
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Figure EV2. Gene network strongly associated with transcriptional variations in the 
PDAC macro-environment. The network was generated by Ingenuity pathway analysis of 
the genes regulated in the PDAC macro-environment. A red node indicates that a gene is up-
regulated compared to normal pancreas, while green represents down-regulation. Darker 
colours indicate stronger regulation. A grey colour stands for genes that did not show any 
apparent variation of their transcript levels. Proteins that are associated with the pathways of 
Pancreatic Adenocarcinoma Signalling, ILK Signalling and mTOR Signalling are highlighted 
in light blue. 
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Figure EV3. The frequency of autophagy genes in pathways regulated in the macro-
environment of PDAC. Using the Ingenuity pathway finder software, genes are shown that 
contribute to the Pancreatic Adenocarcinoma Signalling (A) and the ILK (B) pathways. 
Genes that are functionally associated with autophagy are marked by blue circles. Genes 
labelled in green (down-regulation) or red (up-regulation) exhibited significant changes in 
their expression level in the macro-environment of PDAC compared to healthy tissue (Tab. 
EV4). Solid lines indicate direct interactions between proteins, dotted lines stand for indirect 
interactions. 
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Figure EV4. ACTB, PKM2, PRAF2 and PLK4 mRNA expression in normal, peritumoral 
and PDAC tissue obtained by qRT-PCR. Each bar represents the results from 60 
measurements: three replicate analyses each performed on 20 randomly selected samples 
of the respective tissue type. The values were normalised by reference gene BUD13 and 
relative fold-changes (FC) were calculated in comparison to the mean of all normal tissues.  
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Figure EV5. Heatmap representing the colour-coded expression levels of the 15 genes 
of the prognostic gene signature. Columns represent individual samples; each row stands 
for a gene. Blue and red indicates up- and down-regulation, respectively. The sample types 
are indicated at the top: normal pancreas (N; blue), macro-environment of cystic tumours 
(N.TC; dark-blue), chronic pancreatitis (CP; green), macro-environment of PDAC (N.PDAC; 
purple), PDAC (red) and cystic tumour (TC; yellow).  
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EXPANDED VIEW TABLES 
 
Table EV1. Genes that exhibited significant changes at the transcript level in the 
various kinds of tissue compared to samples from healthy donors. 
 
Table EV2. List of transcripts that were regulated in PDAC and its macro-environment 
but not in chronic pancreatitis. 
 
Table EV3. Transcript variation of the 73 genes associated with the gene network of 
the PDAC macro-environment (Fig. EV2). Their expression variations are shown in PDAC, 
its macro-environment and in CP, respectively, in comparison to healthy tissue.  
 
Table EV4. Transcriptional variations of autophagy-related genes in PDAC, cystic 
tumours, their respective cellular macro-environments and chronic pancreatitis.  
 
Table EV5. List of all differentially expressed autophagy transcripts that were 
statistically linked to survival time.  
 
 
